NCT01814761View on ClinicalTrials.gov

A Study of Bimatoprost 0.01% in the Clinical Setting

CompletedOBSERVATIONAL

Enrollment

312

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Glaucoma, Primary Open AngleOcular Hypertension

Interventions

DRUG

Bimatoprost 0.01%

One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.

Trial Locations (1)

Unknown

Taichung

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Allergan

INDUSTRY